ClinicalTrials.gg
RecruitingNCT04373564ODYSSEYUpdated Jan 22, 2026

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

A Phase 4 interventional study of Motor Tests and Cognitive Tests in Motor Function, Cognitive Function and Contrast Media, sponsored by Guerbet. Recruiting at 51 sites in 8 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Guerbet · Phase 4, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,076
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA.

The study aims to create detailed images of the organs and tissue of the human body during x-ray, CT-scan or MRI investigations, doctors are using contrast media (a kind of dye) which can be given to patients by injection into a blood vessel or by mouth.

In this study researchers want to find out whether so called gadolinium-based contrast agents (GBCAs) have an effect on body movement and mental skills when given to participants multiple times within 5 years.

The study plans to enroll about 2076 participants suffering from a condition for which they are likely to have at least annually a MRI or another imaging examinations. Only adults up to 65 years will be considered to join this study. During the study duration of 5 years participants will receive annually a MRI or other imaging tests (such as CT-scan, x-ray) and will visit the study doctor at least 7 times for physical examinations, laboratory investigations and tests on body movement and mental skills.

Read the detailed description

The primary objective of the study is to assess the potential effect of repeated exposure to either a linear or a macrocyclic gadolinium-based contrast agent (GBCA) on change from baseline to Year 5 in composite measure of motor and cognitive function among neurologically normal adults in comparison to a matched non-GBCA- exposed control group.

The secondary objectives comprise the assessment of the following endpoints in GBCA-exposed participants as compared to controls a) changes from baseline in composite measure of motor and cognitive function post-baseline on yearly basis (Years 1 to 4); b) changes from baseline in each individual test of motor and cognitive function on yearly basis (Years 1 to 5). Total Gd concentrations in blood and urine samples on yearly basis (Years 1 to 5) and adverse events will be collected as secondary objectives.

Of note : The study is considered interventional because of the addition of UE-MRI scans for all participants, as well as blood sampling and the administration of the motor and cognitive tests. The GBCA administered as part of the contrast-enhanced MR imaging in the experimental arms is not the intervention in this study. Neither the protocol nor the investigators assign patients to a specific GBCA as part of the study, making this part of the study observational rather than interventional. The participants were already scheduled, prior to study screening, to undergo CE-MRI as part of their clinical care. The choice of GBCA for the CE-MRI will be based on medical need and institutional usage of GBCA, independent of study participation.

02

Conditions studied

  • Motor Function
  • Cognitive Function
  • Contrast Media

Keywords

  • Motor function assessment
  • Cognitive function assessment
  • Magnetic Resonance Imaging (MRI)
  • Gadolinium
  • Gadolinium-based contrast agent (GBCA)
  • Gadolinium retention
  • Breast cancer
  • Prostate cancer
  • Hepatocellular carcinoma
  • Colorectal cancer
  • Neuroendocrine tumor
  • Branch-duct intraductal papillary mucinous neoplasm (IPMN) of the pancreas
03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's planned enrollment of 2,076 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be neurologically normal, defined as free of unstable neurologic and psychiatric disease as confirmed by a normal neurologic examination at screening
  • Participant (GBCA-exposed or controls) agrees to undergo unenhanced magnetic resonance imaging (UE-MRI) of the brain at enrollment and at the end of the observation period (5 years)
  • Participants should have at least 1 of the following indications: a) Medium to high risk for breast cancer or dense breasts undergoing breast cancer screening with MRI, b) Elevated prostate-specific antigen (PSA) and under active diagnostic surveillance for prostate cancer, c) Chronic liver disease (eg, liver cirrhosis limited to Child class A, post-hepatitis chronic hepatopathy, or primary sclerosing cholangitis) for surveillance of hepatocellular carcinoma development, d) Low-grade colorectal cancer or neuroendocrine tumor undergoing screening for liver or e) Branch-duct intraductal papillary mucinous neoplasm (IPMN) of the pancreas (maximum size ≤2 cm) undergoing imaging surveillance.

In addition, for participants in the GBCA Arms only:

  • Each participant should be likely to undergo ≥5 GBCA-enhanced MR examinations with the same GBCA at least annually throughout the 5-year study duration
  • Prospective participants with up to 3 well documented GBCA administrations prior to study screening are acceptable, provided that the imaging was performed with the same GBCA as the one to be prospectively used in the study. If the GBCA used cannot be identified, he/she cannot be enrolled.

For the Control Arm:

  • Participants who never had and are not likely to receive any GBCA injection during the course of the study
  • Each control participant must be willing to undergo UE-MRI of the brain at baseline and at Year 5. In Years 1 to 4, the control participants will undergo their clinically indicated UE-MRIs, computed tomography (CT), ultrasound, or X-ray procedures

Exclusion criteria

Exclusion Criteria:

  • As evidenced by history or determined in the neurologic exam at screening, concurrent neurological and/or psychiatric disease (or treatments) that could influence the results of the study's motor and cognitive tests (e.g. Cerebrovascular disease, Multiple sclerosis, Neurodegenerative disease, Malignant disease other than listed in indications, Carcinoid tumors, Epilepsy, Prior neurosurgery, Psychotic disorders or any prior psychotic episode not otherwise specified - any documented prior history of chronic schizophrenia, Remittent or current medically confirmed major depressive disorder or bipolar disorder, History of long-term major depression or bipolar affective disorder with an active episode in the past 2 to 5 years, Neurodevelopmental disorders (eg, trisomy 21), Uncontrolled severe migraine, Uncontrolled or controlled anxiety or depression within 6 months before enrollment, Screening scores of ≤24 on the and/or ≥11 on the Hospital Anxiety and Depression Scale (HADS)).
  • Prior, planned, or ongoing chemotherapy or brain irradiation
  • Use of concomitant medication(s) affecting neuro-cognitive or motor function
  • Substance or alcohol abuse as determined by the investigator
  • Alcoholic cirrhosis
  • Renal disease, defined as estimated (eGFR) \< 60 mL/min/1.73 m2
  • History of environmental/occupational/other exposure to one or more chemicals that may affect cognitive and/or motor function, including, but not limited to, heavy metals (arsenic [As], cadmium [Cd], lead [Pb], manganese [Mn], and mercury [Hg]), pesticides, solvents, or carbon monoxide.
  • Clinical indications requiring >1 contrast enhanced magnetic resonance imaging (CE-MRI) every 6 months
  • Pregnant or nursing (lactating) women
  • Presence of any metal-containing joint implants/prostheses

In addition, for participants in either of the GBCA Arms only:

- Receipt of a GBCA or generic prior to study entry other than the specific GBCA to be administered during the course of the study.

For participants in the Control Arm only:

  • Participants with any previous exposure to a GBCA.
  • Participants with any to UE-MRI examinations.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,076 participants (estimated)

Study arms

  • Experimental
    Linear GBCAs

    Adult participants, who were scheduled for repeated enhanced magnetic resonance imaging (MRI), receive a linear gadoliniumbased contrast agent (GBCA, i.e. Eovist/ Primovist, MultiHance or Omniscan) prior to MRI. Each participant will receive the same GBCA throughout the study.

    Procedure: Motor Tests · Procedure: Cognitive Tests · Procedure: Unenhanced-MRI of the brain · Procedure: Gadolinium Measurements · Drug: Gadoxetate disodium · Drug: Gadobenate dimeglumine · Drug: Gadodiamide

  • Experimental
    Macrocyclic GBCAs

    Adult participants, who were scheduled for repeated enhanced magnetic resonance imaging (MRI), receive a macrocyclic gadolinium-based contrast agent (GBCA, i.e. Gadavist/ Gadovist, Dotarem, Magnescope or ProHance) prior to MRI. Each participant will receive the same GBCA throughout the study.

    Procedure: Motor Tests · Procedure: Cognitive Tests · Procedure: Unenhanced-MRI of the brain · Procedure: Gadolinium Measurements · Drug: Gadoterate meglumine · Drug: Gadobutrol · Drug: Gadoteridol

  • Other
    No GBCA (Control arm)

    Adult participants who were never exposed to any gadolinium-based contrast agent and matching the population characteristics of the two GBCA arms. They will not receive any gadolinium-based contrast agent over the study course, but may undergo clinically indicated imaging (e.g. unenhanced magnetic resonance imaging (MRI), unenhanced or enhanced computed tomography, ultrasound and/or X-ray).

    Procedure: Motor Tests · Procedure: Cognitive Tests · Procedure: Unenhanced-MRI of the brain · Procedure: Gadolinium Measurements

Interventions

  • ProcedureMotor Tests

    To assess motor function annually

  • ProcedureCognitive Tests

    To assess cognitive function annually

  • ProcedureUnenhanced-MRI of the brain

    The UE-MRI of the brain will be performed at baseline and at the year 5 visit in order to exclude presence of a significant MRI abnormality

  • ProcedureGadolinium Measurements

    Blood samples and spontaneous urine specimens will be collected through the course of the study to measure Gd concentration

  • DrugGadolinium ethoxybenzyl DTPAStudies of Gadolinium ethoxybenzyl DTPAGadolinium ethoxybenzyl DTPA pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered as defined by the treating physician as part of routine clinical practice

    Also known as: Eovist, Primovist, BAY86-4873

  • DrugGadobenic acidStudies of Gadobenic acidGadobenic acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Administered as defined by the treating physician as part of routine clinical practice

    Also known as: MultiHance

  • Administered as defined by the treating physician as part of routine clinical practice

    Also known as: Omniscan

  • DrugGadoterate meglumine

    Administered as defined by the treating physician as part of routine clinical practice

    Also known as: Dotarem, Magnescope

  • DrugGadobutrol

    Administered as defined by the treating physician as part of routine clinical practice

    Also known as: BAY86-4875, Gadavist, Gadovist

  • DrugGadoteridol

    Administered as defined by the treating physician as part of routine clinical practice

    Also known as: ProHance

06

What researchers measure

Primary outcomes

  1. Change of motor function from baseline to year 5 in comparison to a matched non-GBCA-exposed control group

    The endpoint is a composite z score, defined as the weighted sum of the z scores of the individual tests

    Time frame: At baseline, year 5

  2. Change in cognitive function from baseline to year 5 in comparison to a matched non-GBCA-exposed control group

    The endpoint is a composite z score, defined as the weighted sum of the z scores of the individual tests

    Time frame: At baseline, year 5

Secondary outcomes

  1. Change from baseline in the composite endpoints (motor and cognitive) at each of the post-baseline time points (Years 1 to 4) in GBCA-exposed participants as compared to controls.

    The endpoint is a composite z score, defined as the weighted sum of the z scores of the individual tests

    Time frame: At baseline, years 1, 2, 3, 4

  2. Change from baseline for each of the individual tests (motor and cognitive) at each of the post-baseline time points (Years 1 to 5) in GBCA-exposed participants as compared to controls.

    The endpoint is a composite z score, defined as the weighted sum of the z scores of the individual tests

    Time frame: At baseline, years 1, 2, 3, 4

  3. Number of participants with adverse events

    Time frame: At baseline, years 1, 2, 3, 4, 5

  4. Total Gd concentrations (as measured in a central laboratory) in blood and urine samples taken from exposed and control participants at the time of the annual visit

    Time frame: At baseline, years 1, 2, 3, 4, 5

07

Study locations

25 of 51 sites recruiting
  • Scottsdale Medical Imaging, LLC
    Scottsdale, Arizona 85260, United States
    Recruiting
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
    Recruiting
  • Methodist Medical Center of Illinois
    Peoria, Illinois 61637, United States
    Recruiting
  • Massachussets General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
    • · Contact617-726-8396
    • Mukesh Harisinghani, MD · Principal investigator
  • Boston University Medical Center
    Boston, Massachusetts 02118, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • ActivMed Practices & Research, Inc.
    Methuen, Massachusetts 01844, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University of Massachusetts Memorial Medical Center
    Worcester, Massachusetts 01655, United States
    Terminated

    Not enrolling at this site — choose another above.

  • Department of Radiology
    St Louis, Missouri 63110, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • UNC School of Medicine
    Chapel Hill, North Carolina 27599, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
    Recruiting
  • Albert Einstein Healthcare Network
    Philadelphia, Pennsylvania 19141, United States
    Recruiting
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
    Recruiting
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University of Wisconsin
    Madison, Wisconsin 53792, United States
    Recruiting
  • Hospital Santa Marta
    Taguatinga, Federal District 72025-110, Brazil
    Terminated

    Not enrolling at this site — choose another above.

  • Liga Norte-Rio-Grandense Contra o Câncer
    Natal, Rio Grande do Norte 59075-740, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Instituto Mederi de Pesquisa e Saude
    Passo Fundo, Rio Grande do Sul 99010-120, Brazil
    Recruiting
  • Hospital Moinhos de Vento
    Porto Alegre, Rio Grande do Sul 90035-001, Brazil
    Recruiting
  • Instituto Baía Sul de Ensino e Pesquisa (IEP)
    Florianópolis, Santa Catarina 88020-210, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • CEMEC - Oncológica
    São Bernardo do Campo, São Paulo 09715-090, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto
    São José do Rio Preto, São Paulo 15090-000, Brazil
    Recruiting
    • Luciana Cubas Volpe · Contactlucianacubas@gmail.com · +551732015054
    • Kathia Abdalla · Principal investigator
  • CPCLIN - Centro de Pesquisas Clínicas Ltda.
    São Paulo, São Paulo 01228-200, Brazil
    Terminated

    Not enrolling at this site — choose another above.

  • Albert Einstein Sociedade Beneficente Israelita Brasileira
    São Paulo, São Paulo 05652000, Brazil
    Recruiting
  • CEMEC - Oncológica
    São Bernardo do Campo, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • G. Kenneth Jansz Medical Professional Corporation
    Burlington, Ontario L7N 3V2, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Groupe Hospitalier Pitie-Salpetriere
    Paris, 75013, France
    Withdrawn

    Not enrolling at this site — choose another above.

  • CHU Strasbourg - Hôpital Hautepierre
    Strasbourg, 67200, France
    Recruiting
  • Universitaetsklinikum Tuebingen
    Tübingen, Baden-Wurttemberg 72076, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Vivantes Klinikum Neukoelln
    Berlin, 12351, Germany
    Recruiting
  • A.O.U. Senese Policlinico Santa Maria alle Scotte
    Siena, Siena 53100, Italy
    Recruiting
    • Alfonso Cerase, MD · Principal investigator
  • Azienda Ospedaliera Universitaria di Trieste
    Trieste, Trieste 34125, Italy
    Recruiting
  • Ospedale San Raffaele
    Milan, 20123, Italy
    Recruiting
  • Università Campus Bio-Medico di Roma
    Roma, 00128, Italy
    Recruiting
    • Frederica Spani · Contactf.spani@unicampus.it
    • Carlo Augusto Mallio, MD · Principal investigator
  • Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma)
    Verona, 37134, Italy
    Recruiting
  • BHI of Omsk region "Clinical Oncology Dispensary"
    Omsk, 644013, Russia
    Suspended

    Not enrolling at this site — choose another above.

  • FSBI "National medical scientific center of psychiatry and neurology n.a. V.M. Bekhterev" Adolescent
    Saint Petersburg, 192019, Russia
    Suspended

    Not enrolling at this site — choose another above.

  • FSBI North-West Federal Medical Research Center n.a. V.A. Almazov of MoH RF
    Saint Petersburg, 197341, Russia
    Suspended

    Not enrolling at this site — choose another above.

  • LLC Medical Center Mart
    Saint Petersburg, 199178, Russia
    Suspended

    Not enrolling at this site — choose another above.

  • RSBIH "Smolensk Regional Clinical Hospital"
    Smolensk, 214019, Russia
    Suspended

    Not enrolling at this site — choose another above.

  • Federal State Budgetary Scientific Institution "Tomsk National Research Medical Centre of the Russia
    Tomsk, 634009, Russia
    Suspended

    Not enrolling at this site — choose another above.

  • SBIH Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan
    Ufa, 450054, Russia
    Suspended

    Not enrolling at this site — choose another above.

  • Hallym University Chuncheon Sacred Heart Hospital
    Chuncheon, Gangwon-do 24253, South Korea
    Withdrawn

    Not enrolling at this site — choose another above.

  • Chonnam National University Hospital
    Gwangju, Gyeonggi-do 61469, South Korea
    Withdrawn

    Not enrolling at this site — choose another above.

  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, South Korea
    Recruiting
  • Inje University Busan Paik Hospital
    Busan, 47392, South Korea
    Recruiting
  • Pusan National University Hospital
    Busan, 49241, South Korea
    Recruiting
  • Chosun University Hospital
    Gwangju, 61453, South Korea
    Recruiting
  • Gangnam Severance Hospital, Yonsei University Health System
    Seoul, 06273, South Korea
    Recruiting
    • so hyun Kim · Contactsohyunzang@gmail.com · "+82220194608 -0-0000-0000"
    • Joon Jeong, MD · Principal investigator
  • Chung-Ang University Hospital
    Seoul, 06973, South Korea
    Recruiting
    • DaJeong Kwon · Contactd5301@caumc.or.kr · +821029011336
    • Chang-hwan Choi, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Dec 2028, 93 months after the start.

Of 130 phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 93 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2020
First posted
May 4, 2020
StartActual
Mar 24, 2021
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04373564
Lead sponsor
Guerbet
Collaborators
Bayer AG (Sponsor), Bracco (Sponsor), GEHC (Sponsor)
Responsible party
Sponsor
First posted
May 4, 2020
Start date
Mar 24, 2021
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jan 22, 2026

Study contacts

Nathalie LE FUR, PhD
Contact
nathalie.lefur@guerbet.com
+33649351166
Frantz HEBERT
Contact
frantz.hebert@guerbet.com
+33680249334

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gadolinium ethoxybenzyl DTPA · Gadobenic acid · Gadodiamide

Start the discussion